Beattie A D, Sherlock S
Gut. 1976 Aug;17(8):571-5. doi: 10.1136/gut.17.8.571.
Leucocyte ascorbic acid (LAA) levels were measured in 138 patients with liver disease. Significantly reduced levels were found in 37 patients with alcoholic liver disease (P less than 0-01) and 25 patients with primary biliary cirrhosis (P less than 0-05). In the primary biliary cirrhosis patients, cholestyramine therapy was associated with significantly lower levels of the vitamin (P less than 0-05). Liver ascorbic acid measured in Menghini needle biopsies in 20 patients was significantly correlated with LAA (r=0-807, P less than 0-001). No significant correlation was found between LAA and haematological indices, conventional liver function tests, or cholesterol levels in any group of patients. Patients with LAA levels below 100 nM/10(8) WBC had significantly higher antipyrine half-lives (mean=28-3 h) than patients with LAA levels above this level (mean=18-6 h) (P less than 0-05). Delayed drug metabolism related to low LAA should be considered when drugs metabolised by the liver are prescribed for patients with alcoholic liver disease or primary biliary cirrhosis.
对138例肝病患者测定了白细胞内维生素C（LAA）水平。在37例酒精性肝病患者（P<0.01）和25例原发性胆汁性肝硬化患者（P<0.05）中发现LAA水平显著降低。在原发性胆汁性肝硬化患者中，考来烯胺治疗与维生素水平显著降低相关（P<0.05）。对20例患者进行Menghini针穿刺活检测定肝脏维生素C，其与LAA显著相关（r=0.807，P<0.001）。在任何一组患者中，LAA与血液学指标、传统肝功能试验或胆固醇水平之间均未发现显著相关性。LAA水平低于100 nM/10⁸白细胞的患者，其安替比林半衰期（平均=28.3小时）显著高于LAA水平高于此值的患者（平均=18.6小时）（P<0.05）。当为酒精性肝病或原发性胆汁性肝硬化患者开具有肝脏代谢的药物时，应考虑与低LAA相关的药物代谢延迟。
